Efficacy and Tolerability of Once‐Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Standard Twice‐Weekly Bortezomib and Dexamethasone in Previously Treated Multiple Myeloma with Renal Impairment: Subgroup Analysis from the BOSTON Study
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ajh.26434.
留言 (0)